Search for a trial

A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)

To determine whether treatment with RAD001 10 mg/d plus best supportive care prolongs the progression free survival (PFS) compared to treatment with Placebo plus best supportive care in patients with advanced pancreatic neuroendocrine tumor.

AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION
PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB
STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE
POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT

The objective of the study is to provide access to sunitinib treatment for patients who have completed a prior sunitinib study and are judged by the investigator to have the potential to benefit from sunitinib treatment. During this study the…